Objective: To compare photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) in treating spherical hyperopia using the VISX STAR S2 excimer laser.
Intervention: Fifteen consecutive eyes of 15 patients underwent PRK, and 16 consecutive eyes of 16 patients underwent LASIK (follow-up: 12 months).
Main Outcome Measures: Postoperative pain, uncorrected visual acuity (UCVA), deviation from intended correction, and loss of best spectacle-corrected visual acuity (BSCVA).
Results: Mean preoperative spherical equivalent was + 2.18 diopter [D] for PRK and + 2.03D for LASIK. All PRK patients experienced significant postoperative pain that required systemic medication, whereas LASIK patients had minor and transient discomfort. Mean deviation from intended correction was -0.83D, + 0.01D, and + 0.18D at 1, 6, and 12 months after PRK, and + 0.22D, +0.30D, and + 0.40D at 1, 6, and 12 months after LASIK (P = 0.002 at 1 month). A higher proportion of LASIK eyes had a UCVA of 20/20 or better at all time points (P = 0.013 and 0.025 at 1 and 3 months, respectively). There was no statistically significant difference between both groups in BSCVA loss.
Conclusions: LASIK and PRK are comparable in efficacy and safety. However, PRK was more painful, with an initial and temporary myopic over-correction that did not occur after LASIK. Stability was achieved between 3 and 6 months following PRK, and one month following LASIK.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00140068-200301000-00009 | DOI Listing |
Clin Ophthalmol
December 2024
Hoopes Vision Research Center, Hoopes Vision, Draper, UT, USA.
Anorexia nervosa (AN) is a psychiatric eating disorder characterized by body mass index (BMI) ≤ 18.5, fear of gaining weight, and a distorted perception of body weight. With increasing rates of myopia, there is a population of patients who concurrently develop AN and may seek corneal refractive surgery.
View Article and Find Full Text PDFClin Ophthalmol
December 2024
PersonalEyes, Sydney, NSW, Australia.
Clin Ophthalmol
December 2024
Alcon Vision LLC, Fort Worth, TX, USA.
Purpose: To compare the refractive prediction accuracy of the Optiwave Refractive Analysis (ORA) SYSTEM with the Barrett True-K (BTK) formula in calculating intraocular lens (IOL) power in eyes that underwent cataract surgery after previous myopic photorefractive keratectomy (PRK) or laser-assisted in situ keratomileusis (LASIK).
Methods: This retrospective study evaluated patients aged ≥22 years with prior myopic PRK or LASIK who underwent unilateral or bilateral cataract removal and monofocal IOL implantation using the ORA SYSTEM at 177 sites in the United States. Two datasets were analyzed: All Eyes (ie, all eligible eyes) and First Surgery Eyes (ie, each patient's first implanted eye).
BMC Ophthalmol
December 2024
Shanghai Eye Diseases Prevention &Treatment Center, Shanghai Eye Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: Long-term hyperopia shift is a rare complication following cataract surgery, presenting significant clinical challenges in analysis and management.
Case Presentation: A 52-year-old female with a history of high myopia and laser-assisted in-situ keratomileusis (LASIK) surgery presented with decreased vision in her left eye at the very fifth year after cataract surgery. The spherical equivalent in her left eye had increased to + 6.
Arch Soc Esp Oftalmol (Engl Ed)
December 2024
Clínica Novovisión, Madrid, Spain; Hospital Universitario «Príncipe de Asturias», Universidad de Alcalá, Madrid, Spain.
Purpose: To evaluate the incidence and causes of the need for retreatment after LASIK-induced monovision in patients with myopia and presbyopia without a previous trial of contact lens induced monovision.
Design: Retrospective, observational study.
Methods: We retrospectively studied 914 eyes of 457 consecutive myopic patients with presbyopia scheduled for LASIK-induced monovision (nondominant eye corrected for near).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!